HURA ▲ +1.8% - TuHURA Biosciences, Inc. $HURA HURA - TuHURA Biosciences Provides First Look at Data from its Open-Label Study of IFx-2.0 as an Adjunctive Therapy to Keytruda® in First Line Treatment of Patients with Deep Seated Metastatic Merkel Cell Carcinoma 26-OCT-2026 07:30 AM ET